Evidence Level
Strontium is a trace mineral known for its role in bone health, particularly in the prescription form strontium ranelate. The SOTI trial (Meunier et al., 2004) and TROPOS trial (Reginster et al., 2005) demonstrated that strontium ranelate reduces vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. A meta-analysis by Kanis et al. (2011) confirmed its efficacy, showing a 31% reduction in clinical fractures and a 40% reduction in vertebral fractures. However, concerns about cardiovascular risks led regulatory agencies to restrict its use.
Strontium citrate, available over-the-counter, lacks robust evidence from large-scale randomized controlled trials (RCTs). A limitation of strontium is its artificial inflation of dual-energy X-ray absorptiometry (DEXA) readings by approximately 10%, potentially overestimating bone mineral density gains.
Emerging research highlights strontium's potential beyond osteoporosis treatment. A systematic review and meta-analysis by Shi et al. (2017) found that strontium-modified titanium implants significantly enhance bone-to-implant contact in animal models. Additionally, Yan et al. (2022) demonstrated that strontium-doped calcium phosphate enhances new bone formation in animal studies.
Despite its benefits, the use of strontium ranelate remains cautious due to cardiovascular risks, and further research is needed to establish the safety and efficacy of non-prescription forms.